Since autophagy is a known mechanism of ER+ tumor resistance to CDK4/6 inhibitors, future studies should focus on repeating this experiment with models of this subtype of breast cancer to confirm that this mechanism of overcoming resistance is also valid in the ER+ population. This evidence concerns the gene ESR1 and breast carcinoma.